Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

NCT00994643 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

High Risk Non-Hodgkin's Lymphoma

Interventions

BIOLOGICAL: Rituximab
BIOLOGICAL: Interleukin-2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University